Itolizumab demonstrated clinical efficacy after 12 weeks of treatment, achieving a clinical remission rate of 23.3% compared to 20.0% for adalimumab and 10.0% for placebo
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Itolizumab was generally well tolerated consistent with prior clinical experience
https://www.businesswire.com/news/home/20250206241338/en/(Graphic
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.